Trials / Completed
CompletedNCT02020876
Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations
GenomeDx Decipher Test for Metastatic Disease in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Physician Decision Making?
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21 (actual)
- Sponsor
- GenomeDx Biosciences Corp · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Accepted
Summary
This clinical utility study pilot is based on a review of real but de-identified and randomized patient cases and aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the Decipher test. This is a pilot study and the primary intent is to help guide development and design of future clinical utility studies for Decipher
Detailed description
The primary and secondary objectives will be assessed in retrospectively selected prostate cancer patients treated with radical prostatectomy with one or more adverse pathological features (APFs)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | DECIPHER Questionnaire | Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases. |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-01-01
- Completion
- 2013-12-01
- First posted
- 2013-12-25
- Last updated
- 2013-12-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02020876. Inclusion in this directory is not an endorsement.